3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
52
Ovarian Neoplasms
40
Multiple Myeloma
20
Fallopian Tube Neoplasms
13
Lymphoma
12
Sarcoma
11
Carcinoma, Ovarian Epithelial
11
Triple Negative Breast Neoplasms
8
Recurrence
8
Lymphoma, Large B-Cell, Diffuse
8
Neoplasms
7
Lymphoma, Non-Hodgkin
7
Hodgkin Disease
6
Neoplasms, Plasma Cell
5
Sarcoma, Ewing
4
Prostatic Neoplasms
4
Neoplasm Metastasis
4
Lymphoma, Mantle-Cell
4
Burkitt Lymphoma
4
Rhabdomyosarcoma
3
Osteosarcoma
3
Lymphoma, T-Cell, Peripheral
3
Leiomyosarcoma
3
Breast Neoplasms, Male
3
Uterine Cervical Neoplasms
2
Solid Tumors
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell
2
Interventions
Sorafenib
131
lenvatinib
115
Bevacizumab
88
Radiosurgery
69
atezolizumab
55
sintilimab
54
Nivolumab
51
durvalumab
43
Hepatectomy
43
Fluorouracil
42
apatinib
41
Oxaliplatin
41
camrelizumab
38
Radiofrequency Ablation
38
pembrolizumab
36
Radiotherapy
36
tislelizumab
35
Leucovorin
31
Magnetic Resonance Spectroscopy
30
Immune Checkpoint Inhibitors
28
Doxorubicin
28
Folfox protocol
26
tremelimumab
25
regorafenib
25
Cisplatin
20
spartalizumab
19
donafenib
19
Gemcitabine
19
Cyclophosphamide
19
toripalimab
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Hepatocellular
×
liposomal doxorubicin
×
Clear all
NCT02527772
2019-06-04
LD-FOX4/HCC
Guangxi Medical University
Phase 2/3
Withdrawn